{
  "id": 5349024,
  "title": "AbbVie claims Phase 3 win for multiple myeloma drug etentamig",
  "url": "https://urgent.news/2026/09/03/abbvie-claims-phase-3-win-for-multiple-myeloma-drug-etentamig",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T14:50:40.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/abbvie-claims-phase-3-win-for-multiple-myeloma-drug-etentamig/"
  },
  "original_language": "en",
  "account": null,
  "summary": "AbbVie said its T cell engager etentamig cut the risk of disease progression or death by 60% compared with standard therapies in a Phase 3 multiple myeloma trial. The Chicago-area company is now planning to ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Superluminal secures $60M for Phase 1 of genetic obesity drug",
        "url": "https://urgent.news/2026/09/03/superluminal-secures-60m-for-phase-1-of-genetic-obesity-drug",
        "published": "2026-09-03T10:00:59.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}